Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.

Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM.

Oncologist. 2019 Sep 9. pii: theoncologist.2019-0372. doi: 10.1634/theoncologist.2019-0372. [Epub ahead of print]

PMID:
31501271
2.

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.

Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ.

Eur Urol Oncol. 2019 Jul 1. pii: S2588-9311(19)30079-3. doi: 10.1016/j.euo.2019.06.004. [Epub ahead of print]

PMID:
31272939
3.

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.

Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ.

Eur Urol. 2019 Oct;76(4):418-424. doi: 10.1016/j.eururo.2019.05.010. Epub 2019 Jun 6.

PMID:
31176622
4.

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare.

Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME.

J Immunother Cancer. 2019 May 14;7(1):126. doi: 10.1186/s40425-019-0597-x.

5.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM.

Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.

PMID:
31075726
6.

Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry.

Gerdtsson E, Pore M, Thiele JA, Gerdtsson AS, Malihi PD, Nevarez R, Kolatkar A, Velasco CR, Wix S, Singh M, Carlsson A, Zurita AJ, Logothetis C, Merchant AA, Hicks J, Kuhn P.

Converg Sci Phys Oncol. 2018 Mar;4(1). pii: 015002. doi: 10.1088/2057-1739/aaa013. Epub 2018 Jan 16.

7.

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM Jr, Sternberg CN, Pandite LN, Heymach JV.

Br J Cancer. 2017 Aug 8;117(4):478-484. doi: 10.1038/bjc.2017.206. Epub 2017 Jul 6.

8.

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.

Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM.

Oncotarget. 2017 Jun 27;8(26):42149-42158. doi: 10.18632/oncotarget.15011.

9.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

10.

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.

Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. Epub 2016 Oct 3.

11.

Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters.

Carlsson A, Kuhn P, Luttgen MS, Dizon KK, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis CJ, Zurita AJ.

Clin Cancer Res. 2017 Apr 1;23(7):1722-1732. doi: 10.1158/1078-0432.CCR-16-1355. Epub 2016 Oct 4.

12.

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.

Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG.

BMC Cancer. 2016 Sep 6;16:721. doi: 10.1186/s12885-016-2723-1.

13.

Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity.

Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R.

Am J Pathol. 2016 Aug;186(8):2162-2170. doi: 10.1016/j.ajpath.2016.04.013. Epub 2016 Jun 16.

14.

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME.

J Clin Oncol. 2016 Jun 1;34(16):1913-20. doi: 10.1200/JCO.2015.65.3154. Epub 2016 Apr 4.

15.

8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.

Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ.

PLoS One. 2015 Aug 27;10(8):e0135962. doi: 10.1371/journal.pone.0135962. eCollection 2015.

16.

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM.

Oncologist. 2015 Oct;20(10):1140-8. doi: 10.1634/theoncologist.2015-0143. Epub 2015 Aug 25.

17.

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):276-80. doi: 10.1038/pcan.2015.23. Epub 2015 May 26.

18.

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens.

Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Cardó-Vila M, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R.

Clin Cancer Res. 2015 Jul 1;21(13):3041-51. doi: 10.1158/1078-0432.CCR-13-3059. Epub 2015 Mar 16.

19.

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV.

Br J Cancer. 2015 Mar 31;112(7):1199-205. doi: 10.1038/bjc.2015.73.

20.

Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis.

Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2521-6. doi: 10.1073/pnas.1424994112. Epub 2015 Feb 6.

21.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.

Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. Erratum in: Sci Transl Med. 2015 May 13;7(287):287er3. Tapia, Elsa M Li-Ning [corrected to Li Ning Tapia, Elsa M].

22.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ.

Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

23.

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.

Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF.

Neuro Oncol. 2012 Nov;14(11):1379-92. doi: 10.1093/neuonc/nos158. Epub 2012 Sep 10.

24.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.

PMID:
22759480
25.

State of the science: an update on renal cell carcinoma.

Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK.

Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25. Review.

26.

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Mateo J, Heymach JV, Zurita AJ.

Mol Diagn Ther. 2012 Jun 1;16(3):151-61. doi: 10.2165/11632590-000000000-00000. Review.

27.

Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Hernandez-Yanez M, Heymach JV, Zurita AJ.

Curr Oncol Rep. 2012 Jun;14(3):221-9. doi: 10.1007/s11912-012-0231-2. Review.

28.

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Gallick GE, Corn PG, Zurita AJ, Lin SH.

Future Med Chem. 2012 Jan;4(1):107-19. doi: 10.4155/fmc.11.161.

29.

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.

Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ.

Ann Oncol. 2012 Mar;23(3):688-94. doi: 10.1093/annonc/mdr349. Epub 2011 Aug 5.

30.

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.

Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV.

Br J Cancer. 2011 Jun 28;105(1):112-7. doi: 10.1038/bjc.2011.186. Epub 2011 Jun 14.

31.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV.

Ann Oncol. 2012 Jan;23(1):46-52. doi: 10.1093/annonc/mdr047. Epub 2011 Apr 4.

32.

Targeting neuropilin-1 in human leukemia and lymphoma.

Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R.

Blood. 2011 Jan 20;117(3):920-7. doi: 10.1182/blood-2010-05-282921. Epub 2010 Nov 9.

33.

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.

Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV.

Cancer. 2009 May 15;115(10 Suppl):2346-54. doi: 10.1002/cncr.24228. Review.

34.

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.

Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229.

35.

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F.

Clin Cancer Res. 2009 Jan 1;15(1):267-73. doi: 10.1158/1078-0432.CCR-08-0432. Erratum in: Clin Cancer Res. 2015 Jun 1;21(11):2652.

36.

A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valente AP, Almeida FC, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R.

PLoS One. 2008;3(10):e3452. doi: 10.1371/journal.pone.0003452. Epub 2008 Oct 20.

37.

Cadherin-11 promotes the metastasis of prostate cancer cells to bone.

Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH.

Mol Cancer Res. 2008 Aug;6(8):1259-67. doi: 10.1158/1541-7786.MCR-08-0077.

38.

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM.

J Clin Invest. 2008 Aug;118(8):2697-710. doi: 10.1172/JCI33093.

39.

Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems.

Ozawa MG, Zurita AJ, Dias-Neto E, Nunes DN, Sidman RL, Gelovani JG, Arap W, Pasqualini R.

Trends Cardiovasc Med. 2008 May;18(4):126-32. doi: 10.1016/j.tcm.2008.03.001. Review.

PMID:
18555185
40.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.

41.

Design and validation of a bifunctional ligand display system for receptor targeting.

Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R.

Chem Biol. 2004 Aug;11(8):1081-91.

42.

Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.

Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W.

Cancer Res. 2004 Jan 15;64(2):435-9.

43.

Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.

Diestra JE, Condom E, Del Muro XG, Scheffer GL, Pérez J, Zurita AJ, Muñoz-Seguí J, Vigués F, Scheper RJ, Capellá G, Germà-Lluch JR, Izquierdo MA.

J Urol. 2003 Oct;170(4 Pt 1):1383-7.

PMID:
14501774
44.

Mapping tumor vascular diversity by screening phage display libraries.

Zurita AJ, Arap W, Pasqualini R.

J Control Release. 2003 Aug 28;91(1-2):183-6. Review.

PMID:
12932650
45.

Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours.

Zurita AJ, Diestra JE, Condom E, García Del Muro X, Scheffer GL, Scheper RJ, Pérez J, Germà-Lluch JR, Izquierdo MA.

Br J Cancer. 2003 Mar 24;88(6):879-86.

Supplemental Content

Loading ...
Support Center